Eyenovia, Inc. (NASDAQ: EYEN) Starts Presentation at 30th Annual ROTH Conference
Eyenovia (NASDAQ: EYEN) is a late-stage biopharmaceutical company engaged in developing a pipeline of ophthalmology products in the United States. The company is building its portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. The company has three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. The company is advancing its two lead assets for glaucoma and mydriasis into phase 3 clinical programs and preparing registration studies for a third OTC product for dry eye. For more information, visit the company’s website at www.eyenoviabio.com. About NetworkNewsWire…







